Last reviewed · How we verify
Allogeneic Mesenchymal Bone Marrow Cells
At a glance
| Generic name | Allogeneic Mesenchymal Bone Marrow Cells |
|---|---|
| Sponsor | Stemedica Cell Technologies, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue (PHASE1)
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
- Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure (PHASE3)
- MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma (PHASE1)
- DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease (PHASE2)
- Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease (PHASE1)
- A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects (PHASE1)
- Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: